Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company that regularly issues news about its interventional glaucoma and dry eye businesses. As a manufacturer of ophthalmic medical devices, the company provides updates on its OMNI® and SION® glaucoma technologies and its TearCare® System for evaporative dry eye disease due to meibomian gland disease.
News for SGHT often includes quarterly and annual financial results, revenue guidance updates, and commentary on operating expenses and restructuring plans. The company uses press releases and Form 8-K filings to report results of operations, changes to loan agreements, and targeted cost-reduction initiatives designed to align its operating structure with long-term objectives.
Clinical and scientific developments are another recurring theme. Sight Sciences highlights peer-reviewed publications, systematic reviews, and meta-analyses evaluating the OMNI Surgical System in primary open-angle glaucoma, including standalone and cataract-combination procedures. It also reports on randomized controlled trials and guideline recognition related to the TearCare System in dry eye disease and meibomian gland disease.
Coverage decisions and reimbursement milestones frequently appear in the company’s announcements. Examples include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure, established by Medicare Administrative Contractors, and expanded coverage policies from commercial insurers for implant-free, minimally invasive glaucoma surgery procedures that include OMNI.
Corporate governance and leadership changes are also disclosed, such as executive promotions, board resignations, and new officer appointments. Investors following SGHT news can expect a mix of financial updates, clinical evidence summaries, reimbursement developments, and corporate actions related to its interventional eye care technologies.
Sight Sciences (Nasdaq: SGHT) has announced FDA approval for its IDE trial aimed at assessing the safety and effectiveness of its new higher volume OMNI device for canal viscodilation in adults with primary open-angle glaucoma (POAG).
The PRECISION clinical trial, a three-armed randomized controlled trial, is set to evaluate the device's efficacy, potentially making it the largest of its kind for minimally invasive glaucoma surgery (MIGS). The study involves 459 patients and compares the higher volume OMNI to the iStent Inject.
Sight Sciences announced it will report its financial results for the quarter ending September 30, 2021, on November 10, 2021. The management will discuss the results in a conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the live and archived webcast through the company’s website or by dialing specified numbers with a passcode. Established in 2011, Sight Sciences focuses on developing products for eye diseases, including the OMNI® Surgical System and TearCare® System.
Sight Sciences (Nasdaq: SGHT) announced promising results from the OLYMPIA trial published in Cornea, aiming to expand the FDA indication for its TearCare® System. This system targets evaporative dry eye disease (DED) caused by meibomian gland dysfunction (MGD), responsible for 86% of DED cases. The trial, enrolling 135 adults, demonstrated non-inferiority of TearCare compared to LipiFlow, showing significant improvements in DED symptoms without serious adverse events. Sight Sciences aims to shift treatment paradigms from drops to device-based interventions.
Sight Sciences has filed a lawsuit against Ivantis, Inc. in the United States District Court for Delaware, alleging infringement of four U.S. patents related to devices and methods for reducing intraocular pressure. The company seeks an injunction to stop the manufacture, use, and sale of Ivantis' Hydrus® Microstent, along with monetary damages for past infringements. CEO Paul Badawi stated this lawsuit aims to protect their market position in canalicular glaucoma surgery. Sight Sciences continues to innovate in glaucoma solutions, enhancing patient care through minimally invasive technologies.
Sight Sciences, a growth-stage medical device company (Nasdaq: SGHT), will participate in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 9:30 am ET. The event will be accessible via a live and archived webcast on their website. Founded in 2011, Sight Sciences focuses on addressing major eye diseases with innovative products like the OMNI® Surgical System and the TearCare® System. For more details, visit their official website.
Sight Sciences (Nasdaq: SGHT) has announced favorable results from a study published in Clinical Ophthalmology, demonstrating the long-term safety and efficacy of the OMNI Surgical System in treating open-angle glaucoma. The 24-month study showed a significant reduction in intraocular pressure (IOP) from 24.6 mmHg to 14.7 mmHg, alongside a decrease in medication use. The results indicate that 100% of subjects achieved at least a 20% IOP reduction. Adverse events were consistent with expected outcomes in similar surgeries, underscoring the potential for OMNI's expanded applications.
Sight Sciences reported impressive financial results for Q2 2021, with total revenue reaching $12.5 million, up 258% year-over-year. Surgical Glaucoma sales surged to $12.0 million, marking a 263% increase, while Dry Eye sales hit $0.5 million, up 169%. The gross margin expanded significantly to 82% from 40% in the previous year. Although the net loss widened to $17.6 million ($1.83 per share), the company completed a successful IPO, raising $253 million in July. For 2021, revenue guidance is projected between $46 million and $48 million.
Sight Sciences, Inc. (Nasdaq: SGHT) will announce its financial results for Q2 2021 on August 12, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on developing medical devices aimed at prevalent eye diseases, currently marketing the OMNI® and TearCare® systems. Investors can access the conference call via a live and archived webcast on the company's investor relations website.
Sight Sciences (Nasdaq: SGHT) announced the presentation of new safety and efficacy data from multiple studies of its OMNI Surgical System and TearCare System at the 2021 ASCRS Annual Meeting in Las Vegas from July 23-27. Five papers have been accepted for presentation, focusing on innovative techniques in minimally invasive glaucoma surgery and dry eye treatment. These findings aim to bolster the company's position in addressing prevalent eye diseases.
Sight Sciences, a medical device company, successfully closed its initial public offering (IPO) on July 19, 2021, offering 11.5 million shares at $24.00 each. This includes the full exercise of underwriters' options for an additional 1.5 million shares, resulting in total gross proceeds of approximately $276 million. Trading of Sight Sciences shares commenced on the Nasdaq Global Market under the ticker symbol "SGHT" on July 15, 2021. The offering was managed by Morgan Stanley and BofA Securities, among others.